Parataxis Holdings LLC has committed to investing approximately $18.3 million (KRW 25 billion) in South Korea’s Bridge Biotherapeutics, securing a controlling stake and rebranding the firm as Parataxis Korea.
Once completed, the deal will create South Korea’s first Bitcoin-native treasury platform in the public markets, drawing on Parataxis Capital’s expertise in digital assets. As part of the leadership transition, Edward Chin and Andrew Kim will join the board, with Kim stepping in as CEO. The move signals rising global institutional interest in Bitcoin treasury strategies. The agreement remains subject to shareholder approval, with additional details anticipated in August.
